

Modulatory effects of TGF- β 1 and BMP6 on thecal angiogenesis and steroidogenesis in the bovine ovary

Article

Accepted Version

Mattar, D., Samir, M., Laird, M. and Knight, P. G. (2020) Modulatory effects of TGF- β 1 and BMP6 on thecal angiogenesis and steroidogenesis in the bovine ovary. *Reproduction*, 159 (4). pp. 397-408. ISSN 1470-1626 doi: <https://doi.org/10.1530/REP-19-0311> Available at <https://centaur.reading.ac.uk/88618/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1530/REP-19-0311>

Publisher: BiScientifica

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

1 **Modulatory effects of TGF- β 1 and BMP6 on thecal**
2 **angiogenesis and steroidogenesis in the bovine ovary**

3

4

5 Dareen Mattar, Moafaq Samir, Mhairi Laird, Phil G Knight

6 School of Biological Sciences, University of Reading, Whiteknights, Reading RG6
7 6UB, UK

8

9 MS is now at College of Veterinary Medicine, University of Wasit, Wasit, Iraq

10

11

12 Corresponding author: Phil G Knight

13

14

15

16

17

18

19 *MS: 5391 words (excluding fig. legends and references)*

Abstract

Angiogenesis plays an integral role in follicular and luteal development and is positively regulated by several intra-ovarian factors including vascular endothelial growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2). Various transforming growth factor- β (TGF- β) superfamily members function as intra-ovarian regulators of follicle and luteal function but their potential roles in modulating ovarian angiogenesis have received little attention. In this study, we used a bovine theca interna culture model (exhibiting characteristics of luteinization) to examine the effects of TGF- β 1 and bone morphogenetic protein 6 (BMP6) on angiogenesis and steroidogenesis. VEGFA/FGF2 treatment promoted endothelial cell network formation but had little or no effect on progesterone and androstenedione secretion or expression of key steroidogenesis-related genes. TGF- β 1 suppressed basal and VEGFA/FGF2-induced endothelial cell network formation and progesterone secretion, effects that were reversed by an activin receptor-like kinase 5 (ALK5) inhibitor (SB-431542). The ALK5 inhibitor alone raised androstenedione secretion and expression of several transcripts including *CYP17A1*. BMP6 also suppressed endothelial cell network formation under VEGFA/FGF2-stimulated conditions and inhibited progesterone secretion and expression of several steroidogenesis-related genes under basal and VEGFA/FGF2-stimulated conditions. These effects were reversed by an ALK1/2 inhibitor (K02288). Moreover, the ALK1/2 inhibitor alone augmented endothelial network formation, progesterone secretion, androstenedione secretion and expression of several steroidogenesis-related genes. The results indicate dual suppressive actions of both TGF- β 1 and BMP6 on follicular angiogenesis and steroidogenesis. Further experiments are needed to unravel the complex interactions between TGF- β superfamily signalling and other regulatory factors controlling ovarian angiogenesis and steroidogenesis.

244 words

49 **Introduction**

50 In contrast to most tissues and organs in adult organisms, the ovary is a highly
51 dynamic organ displaying considerable tissue turnover and remodelling associated
52 with recurrent growth and regression of follicles and corpora lutea (CL) throughout
53 the reproductive lifespan of the female (Smith *et al.* 1999, Curry & Osteen 2003).
54 Coordinated endocrine, paracrine and autocrine signals contribute to the regulation of
55 follicle and CL turnover. These signals influence a number of physiological processes
56 in the ovary including somatic cell proliferation, cyto-differentiation and apoptosis,
57 oocyte maturation, steroidogenesis and angiogenesis.

58 Angiogenesis plays an indispensable role in follicle and CL development and is a
59 highly regulated process under the influence of both pro- and anti-angiogenic factors
60 (Gerhardt & Betsholtz 2003, Robinson *et al.* 2009). Key pro-angiogenic factors
61 expressed in the ovary include vascular endothelial growth factor A (VEGFA) and
62 fibroblast growth factor 2, while anti-angiogenic factors include thrombospondins and
63 angiostatin (Berisha *et al.* 2000, Berisha *et al.* 2004, Abramovich *et al.* 2009,
64 Robinson *et al.* 2009, Woad & Robinson 2016). Follicular angiogenesis commences
65 at the preantral stage with the theca layer acquiring a sheath of capillaries by the late
66 secondary follicle stage; these capillaries do not penetrate the basal lamina and so the
67 inner granulosa layer remains avascular until the peri-ovulatory period (Wulff *et al.*
68 2001). Continued follicular growth up to the pre-ovulatory stage is accompanied by
69 further development of the thecal capillary network whereas a decrease in vascularity
70 occurs in atretic follicles (Jiang *et al.* 2003). After ovulation, the remnants of the
71 ruptured follicle undergo transformation into the CL and this is accompanied by a
72 further highly intense phase of angiogenesis, particularly in the early luteal phase
73 when a high proportion of the proliferating cells in the CL are of vascular origin
74 (Jiang *et al.* 2003). The follicular basal lamina breaks down and capillaries from the
75 theca interna layer penetrate the previously avascular granulosa layer.

76 Expression of the pro-angiogenic factors VEGFA and FGF2 is evident in granulosa
77 and theca interna layers of bovine follicles from the secondary stage onwards with
78 expression increasing through antral follicle stages (Berisha *et al.* 2000, Yang &
79 Fortune 2007, Berisha *et al.* 2016). FGF2, FGF receptor (FGFR) and VEGF receptor
80 (VEGFR1/2) mRNA and protein are more abundant in the theca interna than

granulosa layer of large bovine antral follicles (Berisha *et al.* 2000, Berisha *et al.* 2016). The crucial role of VEGFA in driving ovarian angiogenesis is evidenced by the profound inhibition of both follicular (thecal) and luteal angiogenesis observed in marmosets treated with a ‘decoy receptor’ VEGF antagonist (Wulff *et al.* 2001, Wulff *et al.* 2002). Immunoneutralization of VEGF and FGF2 have also been shown to compromise bovine CL function (Yamashita *et al.* 2008, Woad *et al.* 2012). VEGF and FGF2 promote endothelial cell migration and proliferation, acting in a synergistic manner.

Various transforming growth factor- β (TGF- β) superfamily members, including TGF- β itself and several bone morphogenetic proteins (BMP) are expressed in the ovary and have been firmly implicated as autocrine/paracrine factors regulating different aspects of follicle and CL development, including cell proliferation/survival, differentiation and steroidogenesis (Erickson & Shimasaki 2003, Shimasaki *et al.* 2004, Knight & Glister 2006). Thus far, their potential involvement in the regulation of angiogenesis in the ovary has received little attention with only one report, to our knowledge, documenting an inhibitory action of TGF- β 1 on bovine luteal endothelial cell function and capillary morphogenesis (Maroni & Davis 2011). Since the uterine luteolytic signal PGF2 α upregulates luteal expression of TGF- β the authors propose a role for TGF- β in the luteolytic mechanism in ruminants (Maroni & Davis 2011). In contrast, a stimulatory role for TGF- β 1 in follicular angiogenesis was indicated by its ability to enhance secretion of pro-angiogenic factors, including VEGFA, by rat granulosa cells (Kuo *et al.* 2011). Also, BMP7 was found to upregulate VEGFA expression by human granulosa-lutein cells suggesting a positive role in follicular/luteal angiogenesis (Akiyama *et al.* 2014)

TGF- β 1 and TGF- β 2 mRNAs are expressed by sheep ovarian thecal, stromal and vascular cells; vascular cells also expressed TGF- β 3 mRNA (Juengel *et al.* 2004). Signalling receptors for TGF- β (TGFB1 and TGFB2) are expressed by the above cell-types as well as by granulosa cells (Juengel & McNatty 2005) indicative of intrafollicular autocrine/paracrine signalling. Likewise, several BMPs are expressed at the intraovarian level, together with their signalling receptors and extracellular binding proteins (Erickson & Shimasaki 2003, Glister *et al.* 2010). Apart from the aforementioned report of BMP7-induced upregulation of granulosa VEGFA

expression (Akiyama *et al.* 2014) we are not aware of any other studies examining the involvement of BMPs in follicular or luteal angiogenesis.

Despite this, TGF- β and BMPs have been implicated in the regulation of endothelial cell function and angiogenesis in other tissues during normal development and in pathological conditions such as cardiovascular disease and cancer (Cai *et al.* 2012, Peshavariya *et al.* 2014, Guerrero & McCarty 2017). For instance, TGF- β has been shown to exert both pro- and anti-angiogenic actions, in a concentration and cell context-related manner (Orlova *et al.* 2011). Targeted deletion of TGF- β pathway components in mice is embryonically lethal due to disrupted angiogenesis and vasculogenesis (Goumans *et al.* 2009). Microvascular defects associated with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension are linked to perturbations in TGF- β /BMP signalling (Cai *et al.* 2012, Guerrero & McCarty 2017). Likewise, BMP2, BMP4, BMP6, BMP7 and BMP9 have been shown to induce angiogenesis in various in vitro models such as human or bovine aortic endothelial cells (BAEC) or human umbilical vein endothelial cells (HUVEC) (David *et al.* 2009). Several BMPs have been shown to enhance angiogenesis by upregulating VEGF expression (Deckers *et al.* 2002, He & Chen 2005). On the other hand, BMP9 was shown to inhibit VEGF-induced angiogenesis in BAECs (Scharpfenecker *et al.* 2007) while in a HUVEC culture model BMP4 exerted an anti-angiogenic action that was blocked by the BMP antagonist, chordin-like 1 (Kane *et al.* 2008).

Given the paucity of information on the involvement of TGF- β superfamily signalling in follicular angiogenesis, in the present study we utilized a bovine theca interna culture model to investigate the effects of two TGF- β superfamily ligands, TGF- β 1 and BMP6, alone and in combination with selective ALK5 and ALK1/2 inhibitors respectively, on follicular angiogenesis and steroidogenesis. The effects of the ALK inhibitors alone were also examined to seek evidence that endogenous TGF β /BMP ligands modulate angiogenesis and steroidogenesis. Angiogenesis was evaluated by immunohistological analysis of endothelial cell network formation while steroidogenesis was evaluated by measuring steroid secretion (progesterone and androstenedione) and mRNA expression of key steroidogenesis-related genes.

144

145 **Material and methods**

146

147 **Bovine ovaries and collection of theca interna layers**

148 Ovaries from randomly cycling cattle were obtained from a local abattoir and
149 transported to the laboratory in medium-199 supplemented with 1% (v/v) antibiotic
150 antimycotic solution. Theca interna layers were recovered from 4-8mm diameter
151 antral follicles and dissociated into single cells using collagenase digestion as
152 described in detail elsewhere (Glister *et al.* 2005).

153

154 **Follicular angiogenesis cell culture model**

155 An *in vitro* follicular angiogenesis system, which utilizes primary cells derived from
156 the theca interna, was adapted from the method developed by Robinson et al
157 (Robinson *et al.* 2008) for bovine early CL tissue. In this system, tubule-like
158 structures are produced and after seven days in culture, a network of endothelial cells
159 has developed, which resembles a capillary bed.

160 Briefly, sterile coverslips (circular, 19mm diameter x 0.25mm thick; Thermo
161 Scientific, Rochester, NY) were transferred to wells of a 24-well plate (Nuncclon, Life
162 Technologies Ltd, Paisley, UK). One ml of gelatin-based Attachment Factor 1X
163 (Thermo Fisher S006100) was added to each well and incubated at 38.5°C with
164 saturating humidity in 5% CO₂ in air until used. Theca interna cells were seeded onto
165 the coated coverslips at a density of 1×10^5 /ml and cultured for 7 days. The medium
166 used for the first day of culture was supplemented with 2% (v/v) fetal calf serum. This
167 medium consisted of EBM-2 endothelial cell basal medium (500ml; Lonza, CC-4176),
168 supplemented with undefined (proprietary) concentration of hydrocortisone (Lonza,
169 CC-4112A), R3-insulin like growth factor-1 (Lonza, CC-4115A), ascorbic acid
170 (Lonza CC-4116A), human epidermal growth factor (Lonza CC-4317A), antibiotics
171 (GA-1000) (Lonza CC-4381) and heparin (CC-4396A). In-house supplements
172 including apo-transferrin 5µg/ml (Sigma, T-2036) and sodium selenite 5ng/ml (Sigma,

S-9133), insulin 10ng/ml (bovine pancreas, Sigma, I-1882) and BSA 0.1% (Sigma, A-9418) were also added. After the first day of culture, medium was removed and cells were washed with 1ml PBS. Thereafter cells were maintained in serum-free medium for the remainder of the culture period. Medium was changed and treatments applied on day 1, 3 and 5. On day 7 media were either discarded or retained for hormone assay; coverslips with adherent cells were either washed and fixed for subsequent immuno-staining of endothelial cells or lysed using RNeasy lysis buffer (Qiagen) for subsequent isolation of total RNA.

Cell culture treatments

Recombinant bovine FGF2 and VEGFA (R&D systems) were initially dissolved in sterile PBS containing 0.1% bovine serum albumin and 4 mM HCl. Cells were treated with/without these established angiogenic factors at final concentrations of 1 or 10 ng/ml as used previously in a bovine luteal cell angiogenesis model (Robinson et al., 2008). Recombinant human TGF- β 1 (R&D systems) was dissolved in 4mM HCl to give a stock concentration of 10 μ g/ml. Further dilutions were made in sterile culture medium to achieve final concentrations of 0, 0.1, 1 and 10ng/ml in an initial dose-response experiment. Thereafter, 5ng/ml TGF- β 1 was selected as an optimal effective dose in further experiments. SB-431542 (Tocris Biosciences), a potent and selective inhibitor of TGF- β type I receptors ALK4, ALK5, and ALK7 (Vogt *et al.* 2011), was dissolved in ethanol to give a stock concentration of 10mM. Cells were treated with SB-431542 at final concentrations of 2 μ M and 10 μ M. Recombinant human BMP6 (R&D Systems) was dissolved in sterile 4 mM HCl containing 0.1% bovine serum albumin to give a stock concentration of 20 μ g/ml. Further dilutions were made in sterile culture medium to achieve final BMP6 concentrations of 0, 1 and 5ng/ml. The selective inhibitor of BMP-responsive type 1 receptors (ALK1/2/6), K02288 (Tocris), was dissolved in ethanol to give a stock concentration of 10mM. K02288 specifically inhibits the BMP-induced Smad pathway without affecting TGF- β signaling (Sanvitale *et al.* 2013). Cells were treated with K02288 at final concentrations of 2 μ M and 10 μ M.

von Willebrand factor (vWF) immunostaining to identify endothelial cells

At the end of culture, cells were fixed immediately and permeabilized in acetone:methanol (1:1) at 4°C for 5 minutes then washed with PBS (3 x 5 minutes). To block endogenous peroxidase 3% (v/v) hydrogen peroxide in methanol was applied for 10 minutes at room temperature. Plates were washed in PBS buffer (3 x 5 minutes), followed by serum blocking with 20% (v/v) normal goat serum for 30 minutes at room temperature. Polyclonal rabbit anti-human vWF antibody (Dako, High Wycombe, UK) was used at 5µg/ml diluted in 2% (v/v) normal goat serum in PBS. A 200µl of the antibody solution was applied to each well and then incubated in a humidifier box for overnight at 4°C. On the second day, plates were washed in PBS (3 x 5 minutes). The primary antibodies were detected using the ABC Elite (Vector Laboratories, Peterborough, UK) method as follows: biotinylated secondary goat anti-rabbit antibody was diluted 1:250 with 2% (v/v) normal goat serum in PBS and incubated for 30 minutes at room temperature. Plates were then washed in PBS (3 x 5 minutes). The avidin-biotin complex was then prepared according to manufacturer's instructions and applied to each well. After that, plates were incubated for 30 minutes at room temperature followed by further washes in PBS (3 x 5 minutes). Visualisation of bound antibodies was determined using 3,3'-diaminobenzidine tetrahydrochloride (DAB). The DAB solution was prepared according to the manufacturer's instructions and incubated for 2 minutes, after which, the reaction was stopped by washing the wells using distilled water. Plates were counterstained with haematoxylin for 20 seconds, washed in tap water before being dehydrated through a series of alcohols (70% ethanol (v/v) 1 x 5 minutes), (90% ethanol (v/v) 1 x 5 minutes and 100% ethanol (v/v) 2 x 5 minutes. Coverslips were placed in histoclear for (2 x 20 seconds), removed (with cells attached) from the 24-well plates and then mounted on slides using DPX mounting medium. Images of all sections were visualised under 5x objective lens and then captured using an inverted microscope (Zeiss A1 Inverted Epifluorescent Microscope) fitted with a digital camera (Nikon NIS Elements).

Image analysis of vWF immunostaining

A quantification method was developed, based on a protocol previously used to quantify area of vWF staining in a luteal endothelial cell culture (Robinson *et al.* 2008). All image analysis was performed using ImageJ 2.0.0. The areas of brown staining (vWF) were highlighted and only areas stained positively for vWF within endothelial cell clusters were recorded. This was repeated for a total of 25 fields of view across the whole coverslip. In each independent experiment two coverslips were examined for each treatment and from this the mean % area of vWF staining was recorded.

Real-time PCR analysis

Cultured cells were processed for total RNA isolation using Qiagen RNeasy mini kits and cDNA was synthesized from 0.5µg RNA using the AB high capacity cDNA synthesis kit (Fisher Scientific, UK) according to the manufacturer's instructions. cDNA samples were used for real-time PCR analysis of the expression of *NR5A1*, *STAR*, *CYP11A1*, *HSD3B1*, *CYP17A1*, *INSL3* and *LHR*, using the primers listed elsewhere (Glister *et al.* 2013). β -actin (*ACTB*) was used for normalization of gene expression. qPCR reactions were carried out as described previously (Glister *et al.* 2010) using QuantiTect SYBR Green mastermix (Qiagen) and an AB StepOne plus thermal cycler (Applied Biosystems). Relative transcript abundance was evaluated using the $\Delta\Delta C_t$ method (Livak & Schmittgen 2001), with *ACTB* as the initial normalization control. *ACTB* showed uniform expression levels (*Ct* value) amongst the different treatment groups. Expression levels for each transcript were re-normalized to corresponding values in vehicle-treated control cells.

Hormone immunoassays

Androstenedione and progesterone concentrations in cell-conditioned media were determined by competitive ELISA as described previously (Glister *et al.* 2005, Glister *et al.* 2013). Within and between-assay CVs were <10 and 12%, respectively.

Statistical analysis

The effects of the various treatments on endothelial network formation, hormone secretion and gene expression were evaluated by one- and/or two-way analysis of variance (ANOVA) as indicated in results. After one-way ANOVA, *post-hoc* pairwise comparisons amongst different TGF- β -related treatments were made by Fisher's PLSD test. In order to reduce heterogeneity of variance, data were log-transformed prior to statistical analysis. qPCR results were analysed as $\Delta\Delta C_t$ values (i.e. \log^2) before being converted to fold difference values for graphical presentation using the formula $2^{(\Delta\Delta C_t)}$. Results are presented as means \pm SEM of ≥ 3 independent batches of cultured cells, as specified in each figure legend.

Results

Effects of VEGFA and FGF2 on endothelial network formation

Immuno-staining (brown) of endothelial cells using vWF as a marker, revealed that a number of networks had formed in each culture (**Fig. 1**). Each network had a central body of endothelial cells from which a number of branches had developed. These networks appeared to be at different stages of development, with varying size and degree of branching. Statistical analysis showed that there was enhanced formation of endothelial networks in response to co-treatment with VEGFA and FGF2 (hereafter referred to as V/F) at both 1 and 10ng/ml, as indicated by a ~ 5 -fold increase in % area of vWF immuno-staining when comparing to basal level ($P < 0.0001$) (see **Fig. 1d**).

Effect of TGF- $\beta 1$ and ALK5 inhibitor (SB-431542) on endothelial network formation

As above, treatment of cells with V/F alone enhanced endothelial network formation by ~ 4 -fold compared to basal level ($P < 0.02$) (**Fig. 2**). TGF- $\beta 1$ dose-dependently reduced endothelial cell network formation by up to $\sim 90\%$ under both basal and V/F-induced conditions ($P = 0.004$) (Figure 2). As shown in **fig. 3**, treatment with TGF- $\beta 1$ and the ALK5 inhibitor (SB-431542), alone and in combination, promoted marked

differences in the extent of endothelial cell network formation. As observed in the previous experiment, TGF- β 1 (5ng/ml) reduced network formation by ~90% under both basal and V/F-induced conditions. Furthermore, the ALK5 inhibitor at 2 and 10 μ M significantly reversed the inhibitory effect of TGF- β 1 on network formation under both basal and V/F induced conditions.

Effect of BMP6 and ALK1/2 inhibitor (K02288) on endothelial network formation

As in previous experiments, V/F significantly increased endothelial network formation in comparison to basal level ($P < 0.001$) (**Fig. 4**). Treatment with BMP6 decreased V/F-induced endothelial cell network formation by up to ~70% ($P < 0.01$) but did not affect network formation under basal conditions. **Fig. 5** shows that Co-treatment with the BMP inhibitor (K02288) reversed the suppressive action of BMP6 observed under V/F-induced conditions. Moreover, under basal conditions, treatment with the BMP inhibitor alone, or in combination with BMP6, enhanced network formation ~4-fold.

Effect of TGF- β 1 and ALK5 inhibitor (SB-431542) on progesterone and androstenedione secretion

A significant ($P < 0.05$) TGF- β 1-induced decrease in progesterone production was observed under both basal and V/F-induced conditions. This suppressive action of TGF- β 1 was reversed by the TGF- β inhibitor (**Fig. 6A**). Under basal conditions androstenedione concentrations in cell-conditioned media were very low, ~1000-fold lower than progesterone concentrations and less than the assay detection limit in many samples. Treatment with TGF- β inhibitor alone induced a substantial (10 to 100-fold; $P < 0.001$) increase in androstenedione production under both basal and V/F induced conditions. This increase was reversed in cells co-treated with TGF- β 1 (**Fig. 6B**). Two-way ANOVA showed that, overall, V/F treatment did not significantly affect secretion of either progesterone ($P = 0.33$) or androstenedione ($P = 0.15$).

Effects of TGF- β 1 and ALK5 inhibitor on expression of steroidogenesis-related transcripts

Fig. 7 shows the effects of TGF- β 1 and its inhibitor on the relative expression of seven steroidogenesis-related transcripts by theca interna cells cultured under basal and V/F-stimulated conditions. Two-way ANOVA (not shown) indicated significant responses to TGF- β 1 and its inhibitor for all seven transcripts examined (*NR5A1*, *STAR*, *CYP11A1*, *HSD3B1*, *CYP17A1*, *INSL3*, *LHR*) whereas V/F treatment had only a marginal effect on *NR5A1* and *INSL3* transcript abundance. Under basal conditions (without V/F) TGF- β 1 alone did not significantly affect levels of any transcript. However, the TGF- β inhibitor significantly ($P < 0.05$) increased expression of all transcripts with the exception of *NR5A1*. These increases were reversed by TGF- β 1 co-treatment, significantly for all transcripts except *CYP11A1* and *LHR*. Under V/F-stimulated conditions, TGF- β 1 treatment alone significantly ($P < 0.05$) decreased levels of *CYP11A1*, *HSD3B1*, *CYP17A1* and *LHR* while co-treatment with TGF- β inhibitor reversed these effects. Treatment with the TGF- β inhibitor alone increased expression of *NR5A1*, *STAR*, *HSD3B1*, *CYP17A1* and *INSL3* ($P < 0.05$).

Effect of BMP6 and ALK1/2 inhibitor (K02288) on progesterone and androstenedione secretion

Fig. 8A shows that under both basal and V/F induced conditions BMP6 reduced progesterone secretion by ~3-fold. Treatment with 10 μ M BMP6 inhibitor alone greatly increased (20 to 50-fold) progesterone secretion while co-treatment with BMP6 abolished this increase. **Fig. 8B** shows a substantial (~100-fold) increase in androstenedione production in cells treated with 10 μ M of BMP6 inhibitor alone. This increase was reversed in cells co-treated with BMP6, under both basal and V/F-induced conditions. BMP6 alone tended to reduce androstenedione secretion but the effect was not significant. Two-way ANOVA showed that, overall, V/F treatment did not significantly affect secretion of either progesterone ($P = 0.43$) or androstenedione ($P = 0.34$).

Fig. 9 shows the effects of BMP6 and its inhibitor on the relative expression of seven steroidogenesis-related transcripts by theca interna cells cultured under basal and V/F-stimulated conditions. Two-way ANOVA (not shown) indicated that V/F treatment had no overall effect on expression levels of any of the seven transcripts ($P > 0.3$). Under basal conditions (without V/F) BMP6 significantly reduced the abundance of INSL3 and LHR mRNA. However, the BMP inhibitor significantly ($P < 0.05$) increased expression of STAR and CYP11A1 and tended to increase levels of the other five transcripts. In all cases except LHR these numerical increases were reversed ($P < 0.05$) by BMP6 co-treatment. Under V/F-stimulated conditions, BMP6 treatment alone significantly ($P < 0.05$) decreased CYP11A1 expression, an effect reversed by co-treatment with the BMP inhibitor. In addition, treatment with the BMP inhibitor alone increased ($P < 0.05$) the abundance of all seven transcripts and each increase was reversed ($P < 0.05$) by co-treatment with BMP6.

Discussion

During ovarian follicle development *in vivo*, follicular angiogenesis takes place concurrently with steroidogenesis. After ovulation, both processes resume in an intensive manner during follicle luteinization and CL formation (Wulff *et al.* 2001, Fraser *et al.* 2004, Berisha *et al.* 2016). During subsequent CL regression, initiated by the luteolytic action of uterine prostaglandin F2 α (PGF2 α) in ruminants, degeneration of the vascular bed is accompanied by a sharp decline in progesterone secretion.

This study utilized a primary bovine theca interna cell culture model to generate novel information on the modulatory actions on angiogenesis and steroidogenesis of two TGF- β superfamily ligands known to be expressed at the intrafollicular level (TGF- β 1, BMP6). Both ligands were shown to suppress ‘basal’ and/or VEGFA/FGF2-induced angiogenesis and steroidogenesis while pharmacological inhibitors of TGF- β signaling via ALK5 and BMP signaling via ALK1/2 reversed these effects. Both inhibitors also upregulated androstenedione secretion and expression of key steroidogenesis-related genes, including *CYP17A1*.

The ability of endothelial cells from the theca interna layer of follicles to re-assemble, proliferate and form capillary-like networks *in vitro* was demonstrated using a model system in which collagenase-digested theca interna tissue, containing both steroidogenic cells and vascular endothelial cells, was seeded on to gelatin-coated coverslips. To promote endothelial cell network formation, a commercial endothelial cell growth medium supplemented with various proprietary factors was utilized. In agreement with previous findings based on early bovine CL (Robinson *et al.* 2008, Woad *et al.* 2009) we demonstrated a robust increase in the formation of capillary-like networks in response to co-treatment with two well established angiogenic growth factors, VEGFA and FGF2. Despite this marked angiogenic response, VEGFA/FGF2 co-treatment had little or no effect on steroidogenesis in this model, as reflected by secretion of progesterone and androstenedione or expression levels of key genes involved in the steroidogenic pathway. This suggests that the steroidogenic cells of the theca interna layer may lack responsiveness to VEGFA and/or FGF2, at least under the culture conditions used here. Endothelial cells from bovine CL express FGFR, VEGFR1 and VEGFR2 (Gabler *et al.* 2004) but whether steroidogenic cells of the follicular theca interna also express these receptors remains to be established. Co-localization studies using immunohistochemistry and/or *in situ* hybridization could address this issue.

Whilst it is recognised that TGF- β can exert a dual role to either enhance or suppress different aspects of vasculogenesis and angiogenesis (Pepper *et al.* 1993, Orlova *et al.* 2011, Mustafa *et al.* 2012, Guerrero & McCarty 2017), our data for bovine theca interna clearly showed that TGF- β 1 induced a dose dependant inhibition of basal and VEGFA/FGF2-induced endothelial network formation. This action was reversed by a selective ALK5 inhibitor, indicating the likely pathway through which TGF- β signals in this context.

In agreement with our findings, an inhibitory effect of TGF- β 1 on bovine luteal endothelial cell function and capillary morphogenesis has also been reported (Maroni & Davis 2011). Since the uterine luteolytic signal PGF2 α upregulates luteal expression of TGF- β the authors proposed a role for TGF- β in the luteolytic mechanism in ruminants (Maroni & Davis 2011). Indeed, this would be consistent with the TGF- β -induced reduction in thecal progesterone secretion observed in the

present study. TGF- β has also been shown to inhibit progesterone secretion by sheep granulosa cells (Juengel *et al.* 2004). Our findings also concur with a recent study showing that TGF- β 1 dose dependently inhibited endothelial cell network formation in a BAEC culture model (Jarad *et al.* 2017). Additionally, the latter study showed that the inhibitory effect of TGF- β 1 was accompanied by upregulation of the TGF- β accessory receptor endoglin, and Smad2 phosphorylation, but without affecting Smad1/5 phosphorylation. Moreover, TGF- β down regulated VEGFR2 level on the cell surface with a concomitant increase in secreted VEGFR2 level in endothelial cell-conditioned medium, suggesting that the inhibitory action of TGF- β may involve a reduction in VEGFA signalling (Jarad *et al.* 2017). Further work would be required to determine if these considerations apply to the current theca interna culture model. It is also known that TGF- β family members can function in a paracrine manner to activate the production of pro-angiogenic cytokines, including VEGFA, TGF- α and monocyte chemo-attractant protein-1 (MCP1) (Vinals & Pouyssegur 2001, Deckers *et al.* 2002, Ma *et al.* 2007, Kuo *et al.* 2011, Guerrero & McCarty 2017). Additionally, TGF- β family members may modulate the function of other factors such as switching VEGFA from a pro-survival factor into a pro-apoptotic factor for endothelial cells (Ferrari *et al.* 2006, ten Dijke & Arthur 2007).

Various BMPs, including BMP6 studied here, are expressed in the ovary and are recognised as autocrine/paracrine regulators of follicular and luteal cell proliferation and steroidogenesis (Elvin *et al.* 1999, Shimasaki *et al.* 2004, Knight & Glister 2006, Kayani *et al.* 2009). To our knowledge, the potential intraovarian role of BMPs on follicular or luteal angiogenesis has received little attention. However, BMP7 was reported to enhance VEGFA expression by human granulosa-lutein cells (Akiyama *et al.* 2014). Moreover, BMP6 and other related family members are expressed by vascular system cells including endothelial cells and smooth muscle cells suggesting autocrine or paracrine actions on the endothelium (Valdimarsdottir *et al.* 2002). Indeed, BMP6 was suggested to stimulate migration and tube formation of BAECs (Valdimarsdottir *et al.* 2002). In addition, BMP6 induced the proliferation and migration of mouse embryonic endothelial cells, as well as network formation and micro-vessel development in aortic rings (Ren *et al.* 2007, David *et al.* 2009). BMP2 and BMP4 have also been shown to promote angiogenesis by stimulating the secretion of pro-angiogenic growth factors, including VEGFA (Kozawa *et al.* 2001,

Deckers *et al.* 2002).

At variance with these reports, we found that BMP6 reduced VEGFA/FGF2-induced endothelial network formation in our bovine theca interna model, while the selective ALK1/2 inhibitor (K02288) reversed this effect. Moreover, K02288 alone enhanced network formation suggesting blockade of an inhibitory effect of endogenous BMP(s) signaling via ALK1/2. In contrast, we found that the ALK5 inhibitor alone did not enhance network formation above control levels, suggesting an absence of endogenous TGF- β 'tone' suppressing angiogenesis in this model. Since we have found endogenous expression of TGF- β 1, 2 and 3 mRNA in this culture model (data not shown), this is somewhat surprising. It is possible that TGF- β mRNA is not translated or that post-translational processing does not generate bioactive ligand. Alternatively, binding protein(s) and/or coreceptors (betaglycan, endoglin) may modulate binding to signalling receptors (Castonguay *et al.* 2011). Another possible explanation is that the anti-angiogenic effect of endogenous TGF- β is mediated, at least in part, via a different ALK-Smad pathway in endothelial cells. In this context, evidence suggests that TGF- β can also signal via the ALK1/2-Smad1/5 pathway in endothelial cells (Goumans *et al.* 2002, Goumans *et al.* 2003). However, whilst TGF- β signalling via ALK5 elicits an anti-angiogenic response, consistent with our findings in bovine theca interna cells, TGF- β signalling via ALK1/2 evidently enhances angiogenesis in other models (Oh *et al.* 2000, Shao *et al.* 2009, Orlova *et al.* 2011). Evidence for 'cross talk' between ALK5 and ALK1/2-mediated signalling pathways has also been presented for other endothelial cell models, highlighting the complexity of potential regulatory mechanisms governing TGF- β signalling (Goumans *et al.* 2003, Orlova *et al.* 2011).

Our finding that TGF- β and BMP6 elicited similar inhibitory effects on endothelial cell network formation under VEGFA-FGF2-stimulated conditions was unexpected given that they are purported to signal via different type1 receptor-Smad pathways, ALK5-Smad2/3 and ALK1/2-Smad1/5, respectively. However, this was reinforced by the observed ability of the ALK5 and ALK1/2 inhibitors to reverse, respectively, the anti-angiogenic actions of TGF- β and BMP6. Moreover, BMP6 clearly suppressed basal and/or VEGFA/FGF2-induced progesterone secretion and expression of several key steroidogenesis-related genes. This observation is consistent with a previous *in*

vitro study on bovine theca-lutein cells (Kayani *et al.* 2009). The ability of the ALK1/2 inhibitor to reverse the inhibitory effect of BMP6 on progesterone production indicates that the response is likely mediated by the ALK1/2 pathway. However, as observed for the angiogenic response, treatment with the ALK1/2 inhibitor alone promoted substantial increases in secretion of progesterone and androstenedione, accompanied by increased expression of most of the steroidogenesis-related genes examined. As such, these observations reinforce the view that endogenous BMPs expressed by the cultured cells exert a dual suppressive action on both angiogenesis and steroidogenesis. Interestingly, luteal expression of several BMPs, including BMP6, increases during the late luteal phase in bovine (Kayani *et al.* 2009) and human (Nio-Kobayashi *et al.* 2015) consistent with their involvement in luteolysis. Moreover, BMP expression by human granulosa-lutein cells was downregulated by human chorionic gonadotrophin, reinforcing this concept (Nio-Kobayashi *et al.* 2015).

Regarding the gene expression analyses, neither total RNA yield, nor expression levels of the normalization control gene (*ACTB*) were affected by any of the treatments (data not shown). However, it is possible that the observed changes in relative expression levels of steroidogenesis-related genes in our culture model could be due, at least in part, to treatment-induced changes in relative numbers of different cell-types contributing to the total RNA extracted from cell lysates at the end of culture.

It should be noted that culture conditions influence the extent to which follicular theca interna cells undergo luteinisation *in vitro*, as reflected by their morphological phenotype, transcriptional profile and steroid secretory profile (i.e. progesterone to androstenedione ratio) (Campbell *et al.* 1998, Glister *et al.* 2005, Kayani *et al.* 2009). In general, exposure to serum-supplemented media and/or high concentrations of LH, forskolin or insulin promotes luteinisation, accompanied by a substantial increase in progesterone to androstenedione ratio. The culture conditions used in the present endothelial cell culture model (including use of serum-supplemented medium for first day of culture) would be expected to induce some degree of cellular luteinisation. Indeed, the cells formed an adherent monolayer and the progesterone to androstenedione ratio in cell-conditioned medium was very high (>100:1) under all treatment conditions. This contrasts with the progesterone to androstenedione ratio of

~2:1 exhibited by 'non-luteinised' bovine theca interna cells cultured under defined, serum-free conditions (Glister *et al.* 2005). The challenge remains to devise a follicular theca interna angiogenesis culture model that mimics more closely the physiological status of a healthy growing follicle, rather than a luteinizing follicle.

In conclusion, the present results indicate that both TGF- β 1 and BMP6 exert inhibitory actions on ovarian angiogenesis and steroidogenesis, likely mediated by ALK5 and ALK1/2 signalling pathways. Further experiments, beyond the scope of the present study, are needed to unravel the complex interactions between multiple TGF- β superfamily ligands and other regulatory factors implicated in the dual control of ovarian angiogenesis and steroidogenesis at different stages of follicular and luteal development.

Declaration of Interest

The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work

Author contributions

PGK, ML and DM conceived and planned the research; DM, ML and MS performed the experiments and contributed to data analysis and interpretation; PGK drafted the manuscript with input from DM and ML.

Funding

DM was supported by a postgraduate scholarship from the Cultural Bureau of the Royal Embassy of Saudi Arabia. The work was supported, in part, by the United Kingdom Biotechnology and Biological Sciences Research Council (grant no. BB/M001369 to PGK)

Figure Legends

Fig. 1 Development of endothelial cell network in theca interna culture system in response to co-treatment with VEGFA and FGF2 (V/F). Endothelial cells were immuno-stained brown with vWF antibody as shown in representative images of (A) control cells; (B) cells treated with 1ng/ml V/F; (C) cells treated with 10ng/ml V/F; (D) % area of vWF immunostaining based on quantitative analysis of images from 5 independent cultures. Values are means and bars indicate SEM. ***P<0.001 versus controls. Scale bars indicate 100 μ m.

Fig. 1





Fig. 2 The effect of TGF- β 1 alone and in combination with VEGFA and FGF2 (V/F) on network formation by cultured theca interna cells. Values are means and bars

551 indicate SEM (n=3 independent batches of cells); two-way ANOVA results are
 552 shown.

Fig. 2



553

554 **Fig. 3A** Effect of TGF-β1 and the ALK5 inhibitor (SB-431542), alone and in
 555 combination, on basal and VEGFA/FGF (V/F)-induced network formation in cultured
 556 theca interna cells. Values are means and error bars indicate SEM (n=5 independent
 557 batches of cells). Separate one-way ANOVA and *post-hoc* pairwise comparisons were
 558 made for cells cultured with and without V/F; means without a common letter are
 559 significantly different (P < 0.05). **B** shows representative images of cells treated with
 560 vehicle, TGF-β1 and SB-431542 (2μM) in the presence and absence of V/F. Scale
 561 bars = 100 μm.

Fig. 3





Fig. 4 Effect of BMP6 in the presence/absence of VEGFA and FGF2 (V/F) on network formation by cultured theca interna cells. Values are means and error bars indicate SEM (n=3 independent batches of cells); two-way ANOVA results are shown.

Fig. 4



567

568 **Fig. 5A** Effect of BMP6 and BMP inhibitor (K02288), alone and in combination, on
 569 basal and VEGFA/FGF2 (V/F)-induced network formation in cultured theca interna
 570 cells. Values are means and error bars indicate SEM (n=5 independent batches of
 571 cells). Separate one-way ANOVA and *post-hoc* pairwise comparisons were made for
 572 cells cultured with and without V/F; means without a common letter are significantly
 573 different ($P < 0.05$). **B** shows representative images of cells treated with vehicle,
 574 BMP6 and K02288 ($2\mu M$) in the presence and absence of V/F. Scale bars = 100 μm .

Fig. 5





Fig. 6 The effect of TGF- β 1 and its antagonist alone or in combination on basal and VEGFA/FGF2 (V/F)-induced production of (A) progesterone and (B) androstenedione by cultured bovine theca interna cells. Values are means and bars indicate SEM (n=5 independent batches of cells). Separate one-way ANOVA and *post-hoc* pairwise comparisons were made for cells cultured with and without V/F; means without a common letter are significantly different ($P < 0.05$).


Fig. 6



582

583 **Fig. 7** Changes in relative expression of steroidogenesis-related mRNA transcripts in
584 cultured theca interna cells treated with TGF- β 1 and its inhibitor (SB-431542) alone
585 and in combination, under ‘basal’ (open bars) and V/F-stimulated (filled bars)
586 conditions: (A) *NR5A1*; (B) *STAR*; (C) *CYP11A1*; (D) *HSD3B1*; (E) *CYP17A1*; (F)
587 *INSL3*; (G) *LHR*. Values are means and bars indicate SEM (n=5 independent batches
588 of cells) Results of one-way ANOVA and *post-hoc* pairwise comparisons are
589 indicated; means without a common letter are significantly different ($P < 0.05$).

Fig. 7



590

591 **Fig. 8** Effect of BMP6 and its antagonist alone or in combination in the
 592 presence/absence of VEGFA and FGF2 (V/F), on the production of (A) progesterone
 593 and (B) androstenedione by bovine theca layer cultured cells. Values are means and
 594 bars indicate SEM (n=5 independent batches of cells). Separate one-way ANOVA
 595 and post-hoc pairwise comparisons were made for cells cultured with and without
 596 V/F; means without a common letter are significantly different (P < 0.05).

Fig. 8





Fig. 9 Changes in relative expression of steroidogenesis-related mRNA transcripts in cultured theca interna cells treated with BMP6 and the ALK1/2 inhibitor (K02288) alone and in combination, under ‘basal’ (open bars) and V/F-stimulated (filled bars) conditions. (A) *NR5A1*; (B) *STAR*; (C) *CYP11A1*; (D) *HSD3B1*; (E) *CYP17A1*; (F) *INSL3*; (G) *LHR*. Values are means and bars indicate SEM (n=5 independent batches of cells) Results of one-way ANOVA and *post-hoc* pairwise comparisons are indicated; means without a common letter are significantly different ($P < 0.05$).

Fig. 9



References (n=62)

- Abramovich D, Rodriguez Celin A, Hernandez F, Tesone M & Parborell F**
 2009 Spatiotemporal analysis of the protein expression of angiogenic factors and their related receptors during folliculogenesis in rats with and without hormonal treatment. *Reproduction* **137** 309-320.
- Akiyama I, Yoshino O, Osuga Y, Shi J, Harada M, Koga K, Hirota Y, Hirata T, Fujii T, Saito S et al.** 2014 Bone morphogenetic protein 7 increased vascular endothelial growth factor (VEGF)-a expression in human

616 granulosa cells and VEGF receptor expression in endothelial cells.
617 *Reproductive Sciences* **21** 477-482.

618 **Berisha B, Schams D, Kosmann M, Amselgruber W & Einspanier R** 2000
619 Expression and tissue concentration of vascular endothelial growth factor,
620 its receptors, and localization in the bovine corpus luteum during estrous
621 cycle and pregnancy. *Biology of Reproduction* **63** 1106-1114.

622 **Berisha B, Sinowatz F & Schams D** 2004 Expression and localization of
623 fibroblast growth factor (FGF) family members during the final growth of
624 bovine ovarian follicles. *Molecular Reproduction and Development* **67** 162-
625 171.

626 **Berisha B, Schams D, Rodler D & Pfaffl MW** 2016 Angiogenesis in The Ovary -
627 The Most Important Regulatory Event for Follicle and Corpus Luteum
628 Development and Function in Cow - An Overview. *Anatomia Histologia*
629 *Embryologia* **45** 124-130.

630 **Cai J, Pardali E, Sanchez-Duffhues G & ten Dijke P** 2012 BMP signaling in
631 vascular diseases. *FEBS Lett* **586** 1993-2002.

632 **Campbell BK, Baird DT & Webb R** 1998 Effects of dose of LH on androgen
633 production and luteinization of ovine theca cells cultured in a serum-free
634 system. *Journal of Reproduction and Fertility* **112** 69-77.

635 **Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N,**
636 **Sako D, Pearsall RS, Underwood KW, Seehra J et al.** 2011 Soluble
637 Endoglin Specifically Binds Bone Morphogenetic Proteins 9 and 10 via Its
638 Orphan Domain, Inhibits Blood Vessel Formation, and Suppresses Tumor
639 Growth. *Journal of Biological Chemistry* **286** 30034-30046.

640 **Curry TE & Osteen KG** 2003 The matrix metalloproteinase system: Changes,
641 regulation, and impact throughout the ovarian and uterine reproductive
642 cycle. *Endocrine Reviews* **24** 428-465.

643 **David L, Feige JJ & Bailly S** 2009 Emerging role of bone morphogenetic proteins
644 in angiogenesis. *Cytokine & Growth Factor Reviews* **20** 203-212.

645 **Deckers MM, van Bezooijen RL, van der Horst G, Hoogendam J, van Der Bent**
646 **C, Papapoulos SE & Lowik CW** 2002 Bone morphogenetic proteins
647 stimulate angiogenesis through osteoblast-derived vascular endothelial
648 growth factor A. *Endocrinology* **143** 1545-1553.

649 **Elvin JA, Clark AT, Wang P, Wolfman NM & Matzuk MM** 1999 Paracrine
650 actions of growth differentiation factor-9 in the mammalian ovary.
651 *Molecular Endocrinology* **13** 1035-1048.

652 **Erickson GF & Shimasaki S** 2003 The spatiotemporal expression pattern of the
653 bone morphogenetic protein family in rat ovary cell types during the
654 estrous cycle. *Reproductive Biology and Endocrinology* **1** 9.

655 **Ferrari G, Pintucci G, Seghezzi G, Hyman K, Galloway AC & Mignatti P** 2006
656 VEGF, a prosurvival factor, acts in concert with TGF-beta 1 to induce
657 endothelial cell apoptosis. *Proceedings of the National Academy of Sciences*
658 *of the United States of America* **103** 17260-17265.

659 **Fraser HM, Wulff C, Rudge JS & Wiegand S** 2004 Regulation and manipulation
660 of follicular angiogenesis. *Updates in Infertility Treatment 2004* 107-126.

661 **Gabler C, Plath-Gabler A, Killian GJ, Berisha B & Schams D** 2004 Expression
662 pattern of fibroblast growth factor (FGF) and vascular endothelial growth
663 factor (VEGF) system members in bovine corpus luteum endothelial cells
664 during treatment with FGF-2, VEGF or oestradiol. *Reproduction in*
665 *Domestic Animals* **39** 321-327.

666 **Gerhardt H & Betsholtz C** 2003 Endothelial-pericyte interactions in
667 angiogenesis. *Cell and Tissue Research* **314** 15-23.

668 **Glister C, Richards SL & Knight PG** 2005 Bone morphogenetic proteins (BMP) -
669 4, -6, and -7 potently suppress basal and luteinizing hormone-induced
670 androgen production by bovine theca interna cells in primary culture:
671 could ovarian hyperandrogenic dysfunction be caused by a defect in
672 thecal BMP signaling? *Endocrinology* **146** 1883-1892.

673 **Glister C, Satchell L & Knight PG** 2010 Changes in expression of bone
674 morphogenetic proteins (BMPs), their receptors and inhibin co-receptor
675 betaglycan during bovine antral follicle development: inhibin can
676 antagonize the suppressive effect of BMPs on thecal androgen production.
677 *Reproduction* **140** 699-712.

678 **Glister C, Satchell L, Bathgate RA, Wade JD, Dai Y, Ivell R, Anand-Ivell R,**
679 **Rodgers RJ & Knight PG** 2013 Functional link between bone
680 morphogenetic proteins and insulin-like peptide 3 signaling in

modulating ovarian androgen production. *Proceedings of the National Academy of Sciences of the United States of America* **110** E1426-1435.

Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P & ten Dijke P 2002 Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. *Embo Journal* **21** 1743-1753.

Goumans MJ, Lebrin F & Valdimarsdottir G 2003 Controlling the angiogenic switch - A balance between two distinct TGF-beta receptor signaling pathways. *Trends in Cardiovascular Medicine* **13** 301-307.

Goumans MJ, Liu Z & ten Dijke P 2009 TGF-beta signaling in vascular biology and dysfunction. *Cell Res* **19** 116-127.

Guerrero PA & McCarty JH 2017 TGF-beta Activation and Signaling in Angiogenesis. *Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy* 3-23.

He C & Chen X 2005 Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos. *Biochemical and Biophysical Research Communications* **329** 324-330.

Jarad M, Kuczynski EA, Morrison J, Vilorio-Petit AM & Coomber BL 2017 Release of endothelial cell associated VEGFR2 during TGF-beta modulated angiogenesis in vitro. *BMC Cell Biology* **18** 10.

Jiang JY, Cheung CKM, Wang YF & Tsang BK 2003 Regulation of cell death and cell survival gene expression during ovarian follicular development and atresia. *Frontiers in Bioscience-Landmark* **8** D222-D237a.

Juengel JL, Bibby AH, Reader KL, Lun S, Quirke LD, Haydon LJ & McNatty KP 2004 The role of transforming growth factor-beta (TGF-beta) during ovarian follicular development in sheep. *Reproductive Biology and Endocrinology* **2** 78.

Juengel JL & McNatty KP 2005 The role of proteins of the transforming growth factor-beta superfamily in the intraovarian regulation of follicular development. *Human Reproduction Update* **11** 144-161.

Kane R, Godson C & O'Brien C 2008 Chordin-like 1, a bone morphogenetic protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and plays a role in regulating angiogenesis. *Molecular Vision* **14** 1138-1148.

714 **Kayani AR, Glister C & Knight PG** 2009 Evidence for an inhibitory role of bone
 715 morphogenetic protein(s) in the follicular-luteal transition in cattle.
 716 *Reproduction* **137** 67-78.

717 **Knight PG & Glister C** 2006 TGF-beta superfamily members and ovarian follicle
 718 development. *Reproduction* **132** 191-206.

719 **Kozawa O, Matsuno H & Uematsu T** 2001 Involvement of p70 S6 kinase in
 720 bone morphogenetic protein signaling: Vascular endothelial growth factor
 721 synthesis by bone morphogenetic protein-4 in osteoblasts. *Journal of*
 722 *Cellular Biochemistry* **81** 430-436.

723 **Kuo SW, Ke FC, Chang GD, Lee MT & Hwang JJ** 2011 Potential role of follicle-
 724 stimulating hormone (FSH) and transforming growth factor (TGFbeta1)
 725 in the regulation of ovarian angiogenesis. *Journal of Cell Physiology* **226**
 726 1608-1619.

727 **Livak KJ & Schmittgen TD** 2001 Analysis of relative gene expression data using
 728 real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*
 729 **25** 402-408.

730 **Ma J, Wang Q, Fei T, Han JDJ & Chen YG** 2007 MCP-1 mediates TGF-beta-
 731 induced angiogenesis by stimulating vascular smooth muscle cell
 732 migration. *Blood* **109** 987-994.

733 **Maroni D & Davis JS** 2011 TGFB1 disrupts the angiogenic potential of
 734 microvascular endothelial cells of the corpus luteum. *Journal of Cell*
 735 *Science* **124** 2501-2510.

736 **Mustafa DA, Dekker LJ, Stingl C, Kremer A, Stoop M, Sillevius Smitt PA, Kros**
 737 **JM & Luider TM** 2012 A proteome comparison between physiological
 738 angiogenesis and angiogenesis in glioblastoma. *Molecular and Cellular*
 739 *Proteomics* **11** M111 008466.

740 **Nio-Kobayashi J, Trendell J, Giakoumelou S, Boswell L, Nicol L, Kudo M,**
 741 **Sakuragi N, Iwanaga T & Duncan WC** 2015 Bone Morphogenetic
 742 Proteins Are Mediators of Luteolysis in the Human Corpus Luteum.
 743 *Endocrinology* **156** 1494-1503.

744 **Oh SP, Seki T, , Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten**
 745 **Dijke P, Kim S et al.** 2000 Activin receptor-like kinase 1 modulates
 746 transforming growth factor-beta 1 signaling in the regulation of

747 angiogenesis. *Proceedings of the National Academy of Sciences of the*
748 *United States of America* **97** 2626-2631.

749 **Orlova VV, Liu Z, Goumans MJ & ten Dijke P** 2011 Controlling angiogenesis by
750 two unique TGF-beta type I receptor signaling pathways. *Histology and*
751 *Histopathology* **26** 1219-1230.

752 **Pepper MS, Vassalli JD, Orci L & Montesano R** 1993 Biphasic effect of
753 transforming growth factor-beta 1 on in vitro angiogenesis. *Experimental*
754 *Cell Research* **204** 356-363.

755 **Peshavariya HM, Chan EC, Liu GS, Jiang F & Dusting GJ** 2014 Transforming
756 growth factor-beta 1 requires NADPH oxidase 4 for angiogenesis in vitro
757 and in vivo. *Journal of Cellular and Molecular Medicine* **18** 1172-1183.

758 **Ren RQ, Charles PC, Zhang CL, Wu YX, Wang H & Patterson C** 2007 Gene
759 expression profiles identify a role for cyclooxygenase 2-dependent
760 prostanoid generation in BMP6-induced angiogenic responses. *Blood* **109**
761 2847-2853.

762 **Robinson RS, Hammond AJ, Mann GE & Hunter MG** 2008 A novel physiological
763 culture system that mimics luteal angiogenesis. *Reproduction* **135** 405-
764 413.

765 **Robinson RS, Woad KJ, Hammond AJ, Laird M, Hunter MG & Mann GE** 2009
766 Angiogenesis and vascular function in the ovary. *Reproduction* **138** 869-
767 881.

768 **Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, Wang**
769 **Y, Triffitt JT, Cuny GD, Yu PB et al.** 2013 A New Class of Small Molecule
770 Inhibitor of BMP Signaling. *Plos One* **8**.

771 **Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L,**
772 **Lowik CW & ten Dijke P** 2007 BMP-9 signals via ALK1 and inhibits bFGF-
773 induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
774 *Journal of Cell Science* **120** 964-972.

775 **Shao ES, Lin L, Yao Y & Boström KI** 2009 Expression of vascular endothelial
776 growth factor is coordinately regulated by the activin-like kinase
777 receptors 1 and 5 in endothelial cells. *Blood* **114** 2197-2206.

778 **Shimasaki S, Moore RK, Otsuka F & Erickson GF** 2004 The bone
779 morphogenetic protein system in mammalian reproduction. *Endocrine*
780 *Reviews* **25** 72-101.

781 **Smith MF, McIntush EW, Ricke WA, Kojima FN & Smith GW** 1999 Regulation
782 of ovarian extracellular matrix remodelling by metalloproteinases and
783 their tissue inhibitors: effects on follicular development, ovulation and
784 luteal function. *Journal of Reproduction and Fertility Supplement* **54** 367-
785 381.

786 **ten Dijke P & Arthur HM** 2007 Extracellular control of TGF beta signalling in
787 vascular development and disease. *Nature Reviews Molecular Cell Biology*
788 **8** 857-869.

789 **Valdimarsdottir G, Goumans MJ, Rosendahl A, Brugman M, Itoh S, Lebrin F,**
790 **Sideras P & ten Dijke P** 2002 Stimulation of Id1 expression by bone
791 morphogenetic protein is sufficient and necessary for bone
792 morphogenetic protein-induced activation of endothelial cells. *Circulation*
793 **106** 2263-2270.

794 **Vinals F & Pouyssegur J** 2001 Transforming growth factor beta1 (TGF-beta1)
795 promotes endothelial cell survival during in vitro angiogenesis via an
796 autocrine mechanism implicating TGF-alpha signaling. *Molecular and*
797 *Cellular Biology* **21** 7218-7230.

798 **Vogt J, Traynor R & Sapkota GP** 2011 The specificities of small molecule
799 inhibitors of the TGF beta and BMP pathways. *Cellular Signalling* **23** 1831-
800 1842.

801 **Woad KJ, Hammond AJ, Hunter M, Mann GE, Hunter MG & Robinson RS** 2009
802 Temporal Regulation of Luteal Angiogenesis by FGF2 In Vitro. *Biology of*
803 *Reproduction* 174-174.

804 **Woad KJ, Hunter MG, Mann GE, Laird M, Hammond AJ & Robinson RS** 2012
805 Fibroblast growth factor 2 is a key determinant of vascular sprouting
806 during bovine luteal angiogenesis. *Reproduction* **143** 35-43.

807 **Woad KJ & Robinson RS** 2016 Luteal angiogenesis and its control.
808 *Theriogenology* **86** 221-228.

809 **Wulff C, Dickson SE, Duncan WC & Fraser HM** 2001 Angiogenesis in the
810 human corpus luteum: simulated early pregnancy by HCG treatment is

811 associated with both angiogenesis and vessel stabilization. *Human*
812 *Reproduction* **16** 2515-2524.

813 **Wulff C, Wilson H, Wiegand SJ, Rudge JS & Fraser HM** 2002 Prevention of
814 thecal angiogenesis, antral follicular growth, and ovulation in the primate
815 by treatment with vascular endothelial growth factor trap R1R2.
816 *Endocrinology* **143** 2797-2807.

817 **Yamashita H, Kamada D, Shirasuna K, Matsui M, Shimizu T, Kida K, Berisha**
818 **B, Schams D & Miyamoto A** 2008 Effect of local neutralization of basic
819 fibroblast growth factor or vascular endothelial growth factor by a
820 specific antibody on the development of the corpus luteum in the cow.
821 *Molecular Reproduction and Development* **75** 1449-1456.

822 **Yang MY & Fortune JE** 2007 Vascular endothelial growth factor stimulates the
823 primary to secondary follicle transition in bovine follicles in vitro.
824 *Molecular Reproduction and Development* **74** 1095-1104.

825